Barclays Portfolio holdings
Barclays PLC, founded in 1690 by goldsmith bankers in London, is a British multinational financial institution headquartered in London, operating as one of the world’s oldest banks with a significant presence in investment banking, retail banking, and wealth management. Managing billions in assets, Barclays serves millions of customers globally through its retail arm (notably in the UK) and its investment banking division, which excels in trading, mergers and acquisitions, and capital markets, competing with Wall Street giants. The bank has navigated challenges like the 2008 financial crisis—opting for private funding over a government bailout—and has since focused on restructuring, digital innovation, and sustainable finance initiatives. With a rich history and a modern global footprint, Barclays remains a key player in both UK and international financial markets.
Top Buys
| 1 |
KLA
KLAC
|
+$380M |
| 2 |
SPDR S&P 500 ETF Trust
SPY
|
+$319M |
| 3 |
iShares MSCI Emerging Markets ETF
EEM
|
+$293M |
| 4 |
Gilead Sciences
GILD
|
+$242M |
| 5 |
Visa
V
|
+$240M |
Top Sells
| 1 |
Apple
AAPL
|
+$421M |
| 2 |
Wells Fargo
WFC
|
+$363M |
| 3 |
PCP
PRECISION CASTPARTS CORP
PCP
|
+$295M |
| 4 |
Alibaba
BABA
|
+$263M |
| 5 |
IBM
IBM
|
+$237M |
Sector Composition
| 1 | Technology | 12.26% |
| 2 | Healthcare | 11.67% |
| 3 | Financials | 9.34% |
| 4 | Communication Services | 7.79% |
| 5 | Energy | 6.6% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
2026
Radcom
RDCM
$234M
| $172K | ﹤0.01% |
+13,200
| New | +$172K |
|
|
BHR
2027
Braemar Hotels & Resorts
BHR
$203M
| $171K | ﹤0.01% |
15,667
+466
| +3% | +$5.09K |
|
|
SUM
2028
DELISTED
Summit Materials, Inc. Class A Common Stock
SUM
| $171K | ﹤0.01% |
9,375
-2,598
| -22% | -$47.4K |
|
2029
Broadridge
BR
$29.5B
| $170K | ﹤0.01% |
2,890
-5,668
| -66% | -$333K |
|
2030
Brown & Brown
BRO
$30.9B
| $170K | ﹤0.01% |
9,704
-25,930
| -73% | -$454K |
|
2031
ING
ING
$74.7B
| $169K | ﹤0.01% |
15,379
+4,383
| +40% | +$48.2K |
|
2032
Match Group
MTCH
$9.08B
| $169K | ﹤0.01% |
15,313
-139,820
| -90% | -$1.54M |
|
2033
Precigen
PGEN
$1.13B
| $169K | ﹤0.01% |
5,162
-16,397
| -76% | -$537K |
|
2034
Exact Sciences
EXAS
$10.2B
| $168K | ﹤0.01% |
27,979
+17,658
| +171% | +$106K |
|
|
ELGX
2035
DELISTED
Endologix Inc
ELGX
| $168K | ﹤0.01% |
2,099
+1,159
| +123% | +$92.8K |
|
|
IFN
2036
India Fund
IFN
$600M
| $167K | ﹤0.01% |
7,600
| – | – |
|
2037
Surgery Partners
SGRY
$2.8B
| $167K | ﹤0.01% |
12,868
-34,876
| -73% | -$453K |
|
2038
Argan
AGX
$3.18B
| $166K | ﹤0.01% |
4,758
+3,795
| +394% | +$132K |
|
2039
Invesco DB US Dollar Index Bearish Fund
UDN
$147M
| $166K | ﹤0.01% |
7,552
+7,100
| +1,571% | +$156K |
|
|
JAX
2040
DELISTED
J. Alexander's Holdings, Inc.
JAX
| $166K | ﹤0.01% |
16,605
-7,065
| -30% | -$70.6K |
|
2041
HUB Group
HUBG
$2.2B
| $165K | ﹤0.01% |
+8,232
| New | +$165K |
|
2042
LeMaitre Vascular
LMAT
$2.09B
| $165K | ﹤0.01% |
+11,000
| New | +$165K |
|
2043
Medifast
MED
$154M
| $165K | ﹤0.01% |
5,496
+96
| +2% | +$2.88K |
|
2044
TIM SA
TIMB
$10.3B
| $165K | ﹤0.01% |
+15,000
| New | +$165K |
|
|
CMRX
2045
DELISTED
Chimerix, Inc.
CMRX
| $165K | ﹤0.01% |
32,997
-20,976
| -39% | -$105K |
|
|
CRESY
2046
Cresud
CRESY
$518M
| $164K | ﹤0.01% |
16,613
+9
| +0.1% | +$89 |
|
2047
Sarepta Therapeutics
SRPT
$1.82B
| $164K | ﹤0.01% |
8,649
+8,198
| +1,818% | +$155K |
|
|
NPBC
2048
DELISTED
NATL PENN BANCSHARES INC
NPBC
| $164K | ﹤0.01% |
16,363
-24,792
| -60% | -$248K |
|
|
ASCMA
2049
DELISTED
Ascent Capital Group, Inc. Series A
ASCMA
| $164K | ﹤0.01% |
11,695
-414
| -3% | -$5.81K |
|
2050
DHI Group
DHX
$141M
| $163K | ﹤0.01% |
20,373
-3,439
| -14% | -$27.5K |
|